Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes dx.plos.org/10.1371/jour...
Topical formulation of repurposed FDA-approved compounds inhibits Pseudomonas aeruginosa ExoU and improves corneal infection outcomes
Author summary Pseudomonas aeruginosa is a leading cause of microbial keratitis, a sight-threatening infection characterised by rapid tissue destruction. A major contributor to disease severity is the...
dx.plos.org